Lexaria Bioscience Corp. announced on June 11, 2025, that human study GLP-1-H25-5, comparing oral capsules of DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide, has been successfully completed with partial results now available.
The study demonstrated a pronounced reduction in adverse events (AEs) for oral DehydraTECH-liraglutide compared to injected Saxenda®. With IV line-related AEs removed, oral DehydraTECH-liraglutide offered a 22.7% reduction in AEs, including a 67% reduction in nausea and a 31% reduction in overall gastrointestinal AEs.
The differences in measurements of blood glucose, insulin, and body weight across most time points were not statistically significantly different, showing remarkable similarity. These positive findings, particularly the improved tolerability, support a potential expedited FDA regulatory pathway (505(b)(2)) for an orally-delivered liraglutide capsule, addressing an unmet market need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.